APE1 inhibition enhances ferroptotic cell death and contributes to hepatocellular carcinoma therapy
- PMID: 38418695
- PMCID: PMC11043431
- DOI: 10.1038/s41418-024-01270-0
APE1 inhibition enhances ferroptotic cell death and contributes to hepatocellular carcinoma therapy
Abstract
Ferroptosis, a regulated form of cell death triggered by iron-dependent lipid peroxidation, has emerged as a promising therapeutic strategy for cancer treatment, particularly in hepatocellular carcinoma (HCC). However, the mechanisms underlying the regulation of ferroptosis in HCC remain to be unclear. In this study, we have identified a novel regulatory pathway of ferroptosis involving the inhibition of Apurinic/apyrimidinic endonuclease 1 (APE1), a key enzyme with dual functions in DNA repair and redox regulation. Our findings demonstrate that inhibition of APE1 leads to the accumulation of lipid peroxidation and enhances ferroptosis in HCC. At the molecular level, the inhibition of APE1 enhances ferroptosis which relies on the redox activity of APE1 through the regulation of the NRF2/SLC7A11/GPX4 axis. We have identified that both genetic and chemical inhibition of APE1 increases AKT oxidation, resulting in an impairment of AKT phosphorylation and activation, which leads to the dephosphorylation and activation of GSK3β, facilitating the subsequent ubiquitin-proteasome-dependent degradation of NRF2. Consequently, the downregulation of NRF2 suppresses SLC7A11 and GPX4 expression, triggering ferroptosis in HCC cells and providing a potential therapeutic approach for ferroptosis-based therapy in HCC. Overall, our study uncovers a novel role and mechanism of APE1 in the regulation of ferroptosis and highlights the potential of targeting APE1 as a promising therapeutic strategy for HCC and other cancers.
© 2024. The Author(s), under exclusive licence to ADMC Associazione Differenziamento e Morte Cellulare.
Conflict of interest statement
The authors declare no competing interests.
Similar articles
-
PLAG1 interacts with GPX4 to conquer vulnerability to sorafenib induced ferroptosis through a PVT1/miR-195-5p axis-dependent manner in hepatocellular carcinoma.J Exp Clin Cancer Res. 2024 May 14;43(1):143. doi: 10.1186/s13046-024-03061-4. J Exp Clin Cancer Res. 2024. PMID: 38745179 Free PMC article.
-
Ferroptosis in liver cancer: a key role of post-translational modifications.Front Immunol. 2024 Apr 8;15:1375589. doi: 10.3389/fimmu.2024.1375589. eCollection 2024. Front Immunol. 2024. PMID: 38650929 Free PMC article. Review.
-
Protein phosphatase 2A-B55β mediated mitochondrial p-GPX4 dephosphorylation promoted sorafenib-induced ferroptosis in hepatocellular carcinoma via regulating p53 retrograde signaling.Theranostics. 2023 Jul 31;13(12):4288-4302. doi: 10.7150/thno.82132. eCollection 2023. Theranostics. 2023. PMID: 37554285 Free PMC article.
-
Mitochondrial regulation of ferroptosis.J Cell Biol. 2021 Sep 6;220(9):e202105043. doi: 10.1083/jcb.202105043. Epub 2021 Jul 30. J Cell Biol. 2021. PMID: 34328510 Free PMC article. Review.
-
GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis.Cell Death Dis. 2021 Apr 30;12(5):426. doi: 10.1038/s41419-021-03718-4. Cell Death Dis. 2021. PMID: 33931597 Free PMC article.
References
-
- Lang X, Green MD, Wang W, Yu J, Choi JE, Jiang L, et al. Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11. Cancer Discov. 2019;9:1673–85. doi: 10.1158/2159-8290.CD-19-0338. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous